NO944910L - Fremgangsmåte for å inhibere obsessive-kompulsive tilstander og spiseforstyrrelser - Google Patents

Fremgangsmåte for å inhibere obsessive-kompulsive tilstander og spiseforstyrrelser

Info

Publication number
NO944910L
NO944910L NO944910A NO944910A NO944910L NO 944910 L NO944910 L NO 944910L NO 944910 A NO944910 A NO 944910A NO 944910 A NO944910 A NO 944910A NO 944910 L NO944910 L NO 944910L
Authority
NO
Norway
Prior art keywords
eating disorders
obsessive
compulsive
inhibiting
conditions
Prior art date
Application number
NO944910A
Other languages
English (en)
Norwegian (no)
Other versions
NO944910D0 (no
Inventor
Edward Paul Gray
James Joseph Sales
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of NO944910D0 publication Critical patent/NO944910D0/no
Publication of NO944910L publication Critical patent/NO944910L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4535—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a heterocyclic ring having sulfur as a ring hetero atom, e.g. pizotifen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Anesthesiology (AREA)
  • Psychiatry (AREA)
  • Addiction (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
NO944910A 1993-12-21 1994-12-19 Fremgangsmåte for å inhibere obsessive-kompulsive tilstander og spiseforstyrrelser NO944910L (no)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US16848393A 1993-12-21 1993-12-21

Publications (2)

Publication Number Publication Date
NO944910D0 NO944910D0 (no) 1994-12-19
NO944910L true NO944910L (no) 1995-06-22

Family

ID=22611670

Family Applications (1)

Application Number Title Priority Date Filing Date
NO944910A NO944910L (no) 1993-12-21 1994-12-19 Fremgangsmåte for å inhibere obsessive-kompulsive tilstander og spiseforstyrrelser

Country Status (12)

Country Link
EP (1) EP0659428A1 (cs)
JP (1) JPH07196494A (cs)
KR (1) KR950016739A (cs)
CN (1) CN1109331A (cs)
AU (1) AU8155694A (cs)
CA (1) CA2138458A1 (cs)
CZ (1) CZ322494A3 (cs)
HU (1) HUT71466A (cs)
IL (1) IL112046A0 (cs)
NO (1) NO944910L (cs)
RU (1) RU94044323A (cs)
ZA (1) ZA9410076B (cs)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU3953795A (en) * 1994-10-20 1996-05-15 Eli Lilly And Company Bicyclic neuropeptide y receptor antagonists
US6562862B1 (en) 1994-10-20 2003-05-13 Eli Lilly And Company Methods of inhibiting physiological conditions associated with an excess of neuropeptide Y
TW442286B (en) * 1996-02-28 2001-06-23 Pfizer New therapeutic uses of estrogen agonists
IL120266A (en) 1996-02-28 2005-05-17 Pfizer Use of estrogen antagonists and estrogen agonists in the preparation of medicaments for inhibiting pathological conditions

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4133814A (en) * 1975-10-28 1979-01-09 Eli Lilly And Company 2-Phenyl-3-aroylbenzothiophenes useful as antifertility agents
US4418068A (en) * 1981-04-03 1983-11-29 Eli Lilly And Company Antiestrogenic and antiandrugenic benzothiophenes

Also Published As

Publication number Publication date
HU9403656D0 (en) 1995-02-28
JPH07196494A (ja) 1995-08-01
HUT71466A (en) 1995-11-28
KR950016739A (ko) 1995-07-20
IL112046A0 (en) 1995-03-15
EP0659428A1 (en) 1995-06-28
RU94044323A (ru) 1996-11-10
AU8155694A (en) 1995-06-29
CZ322494A3 (en) 1995-08-16
ZA9410076B (en) 1996-06-19
NO944910D0 (no) 1994-12-19
CA2138458A1 (en) 1995-06-22
CN1109331A (zh) 1995-10-04

Similar Documents

Publication Publication Date Title
NO944911L (no) Ikke-peptid-takykininreseptorantagonister
NO944914L (no) Fremgangsmåte for å inhibere autoimmunsykdommer
NO944928L (no) Fremgangsmåter for inhibering av Alzheimers sykdom
NO944919L (no) Fremgangsmåte for å inhibere atrofi av huden eller vagina
MY132056A (en) Methods of inhibiting physiological conditions associated with an excess of neuropeptide y.
DE69432243D1 (de) 2-Phenyl-3-Aroylbenzothiophene zur Behandlung der menstruellen Symptome
NO944927L (no) Fremgangsmåte for inhibering av pulmonar hypertensiv sykdom
KR950010893A (ko) 자궁내막증 억제 방법
DK0651999T3 (da) Fremgangsmåder til inhibering af livmoderfibrose
NO944930L (no) Hemming av dysfunksjonell uterin blödning
NO944934L (no) Hemming av vasomotoriske symptomer og tilhörende psykologiske forstyrrelser i forbindelse med post-menopausalt syndrom
MX9701325A (es) Metodos para inhibir la mucositis ulcerativa.
UA32427C2 (uk) Застосування бензотіофенів або їх фармацевтично прийнятних солей або сольватів для інгібування ангіогенезу і/або ангіогенних захворювань
KR950016731A (ko) 지루 및 좌창의 억제 방법
NO944933L (no) Fremgangsmåte for å inhibere sykdomstilstander i brystet
NO944926L (no) Fremgangsmåter for å inhibere myeloperoksidaseaktivitet
NO944924L (no) Fremgangsmåter for inhibering av Turner's syndrom
NO944917D0 (no) Anvendelse av 2-fenyl-3-aroyltiofener for inhibering av eggstokkdysgenese, forsinket pubertet eller seksuell infantilisme
NO944931L (no) Anvendelse av 2-fenyl-3-aroylbenzotiofener for inhibering av tidlig seksuell modenhet
NO975580L (no) Fremgangsmåte for å inhibere melanom
NO944923L (no) Hemming av vektökning eller indusering av vekttap
NO944910L (no) Fremgangsmåte for å inhibere obsessive-kompulsive tilstander og spiseforstyrrelser
NO973367L (no) Fremgangsmåte for å inhibere miljömessige östrogen
NO973609L (no) Fremgangsmåte for å inhibere effektene av IL-6
NO944577L (no) Hemming av effekten av amyloidogene proteiner